메뉴 건너뛰기




Volumn 94, Issue 2, 2012, Pages 316-323

GLP-1 and cardioprotection: From bench to bedside

Author keywords

Apoptosis; GLP 1; Heart failure; Myocardial infarction; Necrosis

Indexed keywords

ALBIGLUTIDE; CARDIOVASCULAR AGENT; CASPASE 3; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36]; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; LIRAGLUTIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTECTIVE AGENT; REPERFUSION INJURY SALVAGE KINASE; UNCLASSIFIED DRUG;

EID: 84860159344     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs123     Document Type: Review
Times cited : (97)

References (85)
  • 1
    • 77951901715 scopus 로고    scopus 로고
    • Cell death in the pathogenesis of heart disease: Mechanisms and significance
    • Whelan RS, Kaplinskiy V, Kitsis RN. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 2010;72:19-44.
    • (2010) Annu Rev Physiol , vol.72 , pp. 19-44
    • Whelan, R.S.1    Kaplinskiy, V.2    Kitsis, R.N.3
  • 6
    • 1142309743 scopus 로고    scopus 로고
    • New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway
    • Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004;61:448-460.
    • (2004) Cardiovasc Res , vol.61 , pp. 448-460
    • Hausenloy, D.J.1    Yellon, D.M.2
  • 7
    • 34548746306 scopus 로고    scopus 로고
    • Myocardial reperfusion injury
    • Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
    • (2007) N Engl J Med , vol.357 , pp. 1121-1135
    • Yellon, D.M.1    Hausenloy, D.J.2
  • 8
    • 34548008730 scopus 로고    scopus 로고
    • Reperfusion injury salvage kinase signalling: Taking a RISK for cardioprotection
    • DOI 10.1007/s10741-007-9026-1, Special Issue on Cardioprotection; Guest Editors: Dennis V. Cokkinos and Gerd Heusch
    • Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007;12:217-234. (Pubitemid 350176695)
    • (2007) Heart Failure Reviews , vol.12 , Issue.3-4 , pp. 217-234
    • Hausenloy, D.J.1    Yellon, D.M.2
  • 9
    • 33845344395 scopus 로고
    • Plasma insulin response to oral and intravenous glucose administration
    • Elrick H, Stimmler L, Hlad CJ JR, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964;24:1076-1082.
    • (1964) J Clin Endocrinol Metab , vol.24 , pp. 1076-1082
    • Elrick, H.1    Stimmler, L.2    Hlad Jr., C.J.3    Arai, Y.4
  • 11
    • 34248223285 scopus 로고    scopus 로고
    • Biology of incretins: GLP-1 and GIP
    • DOI 10.1053/j.gastro.2007.03.054, PII S001650850700580X
    • Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007; 132:2131-2157. (Pubitemid 46711096)
    • (2007) Gastroenterology , vol.132 , Issue.6 , pp. 2131-2157
    • Baggio, L.L.1    Drucker, D.J.2
  • 12
    • 0028953577 scopus 로고
    • Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo
    • Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995;80:952-957.
    • (1995) J Clin Endocrinol Metab , vol.80 , pp. 952-957
    • Deacon, C.F.1    Johnsen, A.H.2    Holst, J.J.3
  • 13
    • 0030607672 scopus 로고    scopus 로고
    • Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor
    • DOI 10.1016/S0014-2999(96)00795-9, PII S0014299996007959
    • Knudsen LB, Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996;318:429-435. (Pubitemid 27046288)
    • (1996) European Journal of Pharmacology , vol.318 , Issue.2-3 , pp. 429-435
    • Knudsen, L.B.1    Pridal, L.2
  • 14
    • 78650753885 scopus 로고    scopus 로고
    • Incretin-based therapies for type 2 diabetes mellitus: Properties, functions, and clinical implications
    • Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011;124:S3-S18.
    • (2011) Am J Med , vol.124
    • Nauck, M.A.1
  • 15
    • 67649637819 scopus 로고    scopus 로고
    • Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis
    • Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut 2009;58:990-997.
    • (2009) Gut , vol.58 , pp. 990-997
    • Marzioni, M.1    Alpini, G.2    Saccomanno, S.3    Candelaresi, C.4    Venter, J.5    Rychlicki, C.6
  • 16
    • 76449115696 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection
    • Harkavyi A, Whitton PS. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 2010;159:495-501.
    • (2010) Br J Pharmacol , vol.159 , pp. 495-501
    • Harkavyi, A.1    Whitton, P.S.2
  • 17
    • 78649471913 scopus 로고    scopus 로고
    • Gastrointestinal hormones and the regulation of b-cell mass
    • Lavine JA, Attie AD. Gastrointestinal hormones and the regulation of b-cell mass. Ann N Y Acad Sci 2010;1212:41-58.
    • (2010) Ann N y Acad Sci , vol.1212 , pp. 41-58
    • Lavine, J.A.1    Attie, A.D.2
  • 18
    • 77953931504 scopus 로고    scopus 로고
    • Clinical approaches to preserve beta-cell function in diabetes
    • Wajchenberg BL. Clinical approaches to preserve beta-cell function in diabetes. Adv Exp Med Biol 2010;654:515-535.
    • (2010) Adv Exp Med Biol , vol.654 , pp. 515-535
    • Wajchenberg, B.L.1
  • 19
    • 23944479411 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: Role of protein kinase B
    • DOI 10.1007/s00125-005-1787-2
    • Li L, El-KholyW, Rhodes CJ, Brubaker PL. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 2005;48:1339-1349. (Pubitemid 41186100)
    • (2005) Diabetologia , vol.48 , Issue.7 , pp. 1339-1349
    • Li, L.1    El-Kholy, W.2    Rhodes, C.J.3    Brubaker, P.L.4
  • 20
    • 79953173175 scopus 로고    scopus 로고
    • GLP-1-derived nonapeptide GLP-1(28-36) amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes
    • Tomas E, Stanojevic V, Habener JF. GLP-1-derived nonapeptide GLP-1(28-36) amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011;167:177-184.
    • (2011) Regul Pept , vol.167 , pp. 177-184
    • Tomas, E.1    Stanojevic, V.2    Habener, J.F.3
  • 21
    • 84860204551 scopus 로고    scopus 로고
    • Cardiovascular biology of the incretin system
    • doi:10.1210/er.2011-1052
    • Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev 2012;33: doi:10.1210/er.2011-1052.
    • (2012) Endocr Rev , pp. 33
    • Ussher, J.R.1    Drucker, D.J.2
  • 22
    • 84859479993 scopus 로고    scopus 로고
    • Understanding the cardiovascular effects of incretin
    • Yoon JS, Lee HW. Understanding the cardiovascular effects of incretin. Diabetes Metab J 2011;35:437-443.
    • (2011) Diabetes Metab J , vol.35 , pp. 437-443
    • Yoon, J.S.1    Lee, H.W.2
  • 24
    • 81855184473 scopus 로고    scopus 로고
    • The incretin axis in cardiovascular disease
    • Plutzky J. The incretin axis in cardiovascular disease. Circulation 2011;124:2285-2289.
    • (2011) Circulation , vol.124 , pp. 2285-2289
    • Plutzky, J.1
  • 25
    • 43249089631 scopus 로고    scopus 로고
    • Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways
    • DOI 10.1161/CIRCULATIONAHA.107.739938, PII 0000301720080506000007
    • Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008;117:2340-2350. (Pubitemid 351653542)
    • (2008) Circulation , vol.117 , Issue.18 , pp. 2340-2350
    • Ban, K.1    Noyan-Ashraf, M.H.2    Hoefer, J.3    Bolz, S.-S.4    Drucker, D.J.5    Husain, M.6
  • 26
    • 0030013475 scopus 로고    scopus 로고
    • Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
    • DOI 10.1210/en.137.7.2968
    • Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996;137: 2968-2978. (Pubitemid 26192194)
    • (1996) Endocrinology , vol.137 , Issue.7 , pp. 2968-2978
    • Bullock, B.P.1    Heller, R.S.2    Habener, J.F.3
  • 27
    • 0028900758 scopus 로고
    • Tissue-specific expression of the human receptor for glucagon-like peptide-I: Brain, heart and pancreatic forms have the same deduced amino acid sequences
    • Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219-224.
    • (1995) FEBS Lett , vol.358 , pp. 219-224
    • Wei, Y.1    Mojsov, S.2
  • 29
    • 12144260853 scopus 로고    scopus 로고
    • Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury
    • DOI 10.2337/diabetes.54.1.146
    • Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005;54: 146-151. (Pubitemid 40105106)
    • (2005) Diabetes , vol.54 , Issue.1 , pp. 146-151
    • Bose, A.K.1    Mocanu, M.M.2    Carr, R.D.3    Brand, C.L.4    Yellon, D.M.5
  • 31
    • 79960987925 scopus 로고    scopus 로고
    • Cardiovascular effects of glucagonlike peptide-1 agonists
    • Davidson MH. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol 2011;108:33B-41B.
    • (2011) Am J Cardiol , vol.108
    • Davidson, M.H.1
  • 32
    • 78649930490 scopus 로고    scopus 로고
    • GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats
    • Ku HC, Chen WP, Su MJ. GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch Pharmacol 2010;382: 463-474.
    • (2010) Naunyn Schmiedebergs Arch Pharmacol , vol.382 , pp. 463-474
    • Ku, H.C.1    Chen, W.P.2    Su, M.J.3
  • 33
    • 77951168113 scopus 로고    scopus 로고
    • Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice
    • Sauvé M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010;59:1063-1073.
    • (2010) Diabetes , vol.59 , pp. 1063-1073
    • Sauvé, M.1    Ban, K.2    Momen, M.A.3    Zhou, Y.Q.4    Henkelman, R.M.5    Husain, M.6
  • 34
    • 79961172510 scopus 로고    scopus 로고
    • DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion
    • Ku HC, Chen WP, Su MJ. DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol 2011;384:197-207.
    • (2011) Naunyn Schmiedebergs Arch Pharmacol , vol.384 , pp. 197-207
    • Ku, H.C.1    Chen, W.P.2    Su, M.J.3
  • 35
    • 84855171929 scopus 로고    scopus 로고
    • The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure
    • Hlebowicz J, Lindstedt S, Bjorgell O, Dencker M. The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure. Cardiovasc Ultrasound 2011;9:43.
    • (2011) Cardiovasc Ultrasound , vol.9 , pp. 43
    • Hlebowicz, J.1    Lindstedt, S.2    Bjorgell, O.3    Dencker, M.4
  • 36
    • 79851489434 scopus 로고    scopus 로고
    • Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men
    • Nathanson D, Zethelius B, Berne C, Lind L, Andrén B, Ingelsson E et al. Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men. Diabet Med 2011;28:301-305.
    • (2011) Diabet Med , vol.28 , pp. 301-305
    • Nathanson, D.1    Zethelius, B.2    Berne, C.3    Lind, L.4    Andrén, B.5    Ingelsson, E.6
  • 40
    • 77950267745 scopus 로고    scopus 로고
    • Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor
    • Ban K, Kim KH, Cho CK, Sauvé M, Diamandis EP, Backx PH et al. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010;151:1520-1531.
    • (2010) Endocrinology , vol.151 , pp. 1520-1531
    • Ban, K.1    Kim, K.H.2    Cho, C.K.3    Sauvé, M.4    Diamandis, E.P.5    Backx, P.H.6
  • 41
    • 58149342098 scopus 로고    scopus 로고
    • Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia-reoxygenation
    • Xie Y, Wang SX, Sha WW, Zhou X, Wang WL, Han LP et al. Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia-reoxygenation. Chin Med J (Engl) 2008;121:2134-2138.
    • (2008) Chin Med J (Engl) , vol.121 , pp. 2134-2138
    • Xie, Y.1    Wang, S.X.2    Sha, W.W.3    Zhou, X.4    Wang, W.L.5    Han, L.P.6
  • 42
    • 64649102619 scopus 로고    scopus 로고
    • GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice
    • Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009;58:975-983.
    • (2009) Diabetes , vol.58 , pp. 975-983
    • Noyan-Ashraf, M.H.1    Momen, M.A.2    Ban, K.3    Sadi, A.M.4    Zhou, Y.Q.5    Riazi, A.M.6
  • 45
    • 58949084130 scopus 로고    scopus 로고
    • Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury
    • Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-510.
    • (2009) J Am Coll Cardiol , vol.53 , pp. 501-510
    • Timmers, L.1    Henriques, J.P.2    De Kleijn, D.P.3    Devries, J.H.4    Kemperman, H.5    Steendijk, P.6
  • 46
    • 80052072913 scopus 로고    scopus 로고
    • Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: Evidence for improving cardiac metabolic efficiency
    • Bao W, Aravindhan K, Alsaid H, Chendrimada T, Szapacs M, Citerone DR et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One 2011;6:e23570.
    • (2011) PLoS One , vol.6
    • Bao, W.1    Aravindhan, K.2    Alsaid, H.3    Chendrimada, T.4    Szapacs, M.5    Citerone, D.R.6
  • 47
    • 78149300165 scopus 로고    scopus 로고
    • Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart
    • Brown SB, Libonati JR, Selak MA, Shannon RP, Simmons RA. Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart. Cardiovasc Drugs Ther 2010;24:197-205.
    • (2010) Cardiovasc Drugs Ther , vol.24 , pp. 197-205
    • Brown, S.B.1    Libonati, J.R.2    Selak, M.A.3    Shannon, R.P.4    Simmons, R.A.5
  • 48
    • 38149083367 scopus 로고    scopus 로고
    • Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart
    • Sonne DP, Engstrøm T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008;146:243-249.
    • (2008) Regul Pept , vol.146 , pp. 243-249
    • Sonne, D.P.1    Engstrøm, T.2    Treiman, M.3
  • 49
    • 77953807602 scopus 로고    scopus 로고
    • Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits
    • Iwasa M, Kobayashi H, Yasuda S, Kawamura I, Sumi S, Yamada Y et al. Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits. J Cardiovasc Pharmacol 2010;55:625-634.
    • (2010) J Cardiovasc Pharmacol , vol.55 , pp. 625-634
    • Iwasa, M.1    Kobayashi, H.2    Yasuda, S.3    Kawamura, I.4    Sumi, S.5    Yamada, Y.6
  • 50
    • 79961231117 scopus 로고    scopus 로고
    • Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits
    • Iwasa M, Yamada Y, Kobayashi H, Yasuda S, Kawamura I, Sumi S et al. Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits. Br J Pharmacol 2011;164:119-131.
    • (2011) Br J Pharmacol , vol.164 , pp. 119-131
    • Iwasa, M.1    Yamada, Y.2    Kobayashi, H.3    Yasuda, S.4    Kawamura, I.5    Sumi, S.6
  • 52
    • 34548545405 scopus 로고    scopus 로고
    • Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway
    • DOI 10.1007/s10557-007-6030-6
    • Bose AK, Mocanu MM, Carr RD, Yellon DM. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007;21:253-256. (Pubitemid 47387464)
    • (2007) Cardiovascular Drugs and Therapy , vol.21 , Issue.4 , pp. 253-256
    • Bose, A.K.1    Mocanu, M.M.2    Carr, R.D.3    Yellon, D.M.4
  • 53
    • 77951812608 scopus 로고    scopus 로고
    • The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA
    • Ye Y, Keyes KT, Zhang C, Perez-Polo JR, Lin Y, Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010;298: H1454-H1465.
    • (2010) Am J Physiol Heart Circ Physiol , vol.298
    • Ye, Y.1    Keyes, K.T.2    Zhang, C.3    Perez-Polo, J.R.4    Lin, Y.5    Birnbaum, Y.6
  • 54
    • 45349103305 scopus 로고    scopus 로고
    • Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia
    • Huisamen B, Genade S, Lochner A. Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. Cardiovasc J Afr 2008;19:77-83. (Pubitemid 351846438)
    • (2008) Cardiovascular Journal of Africa , vol.19 , Issue.2 , pp. 77-83
    • Huisamen, B.1    Genade, S.2    Lochner, A.3
  • 55
    • 79959966874 scopus 로고    scopus 로고
    • Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats
    • Huisamen B, Genis A, Marais E, Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 2011;25: 13-20.
    • (2011) Cardiovasc Drugs Ther , vol.25 , pp. 13-20
    • Huisamen, B.1    Genis, A.2    Marais, E.3    Lochner, A.4
  • 56
    • 79955692561 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents
    • Dokken BB, La Bonte LR, Davis-Gorman G, Teachey MK, Seaver N, McDonagh PF. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res 2011; 43:300-305.
    • (2011) Horm Metab Res , vol.43 , pp. 300-305
    • Dokken, B.B.1    La Bonte, L.R.2    Davis-Gorman, G.3    Teachey, M.K.4    Seaver, N.5    McDonagh, P.F.6
  • 57
    • 77952889531 scopus 로고    scopus 로고
    • Glucagonlike peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction
    • Dokken BB, Hilwig WR, Teachey MK, Panchal RA, Hubner K, Allen D et al. Glucagonlike peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction. Resuscitation 2010;81:755-760.
    • (2010) Resuscitation , vol.81 , pp. 755-760
    • Dokken, B.B.1    Hilwig, W.R.2    Teachey, M.K.3    Panchal, R.A.4    Hubner, K.5    Allen, D.6
  • 59
    • 69049113026 scopus 로고    scopus 로고
    • Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model
    • Kristensen J, Mortensen UM, Schmidt M, Nielsen PH, Nielsen TT, Maeng M. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 2009;9:31.
    • (2009) BMC Cardiovasc Disord , vol.9 , pp. 31
    • Kristensen, J.1    Mortensen, U.M.2    Schmidt, M.3    Nielsen, P.H.4    Nielsen, T.T.5    Maeng, M.6
  • 60
    • 0037629509 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium
    • DOI 10.1016/S0196-9781(03)00108-6
    • Kavianipour M, Ehlers MR, Malmberg K, Ronquist G, Ryden L, Wikström G et al. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003;24: 569-578. (Pubitemid 36829346)
    • (2003) Peptides , vol.24 , Issue.4 , pp. 569-578
    • Kavianipour, M.1    Ehlers, M.R.2    Malmberg, K.3    Ronquist, G.4    Ryden, L.5    Wikstrom, G.6    Gutniak, M.7
  • 61
    • 0019429079 scopus 로고
    • Coronary collateral circulation in the pig: Correlation of collateral flow with coronary bed size
    • DOI 10.1007/BF01907957
    • White FC, Bloor CM. Coronary collateral circulation in the pig: correlation of collateral flow with coronary bed size. Basic Res Cardiol 1981;76:189-196. (Pubitemid 11102895)
    • (1981) Basic Research in Cardiology , vol.76 , Issue.2 , pp. 189-196
    • White, F.C.1    Bloor, C.M.2
  • 62
    • 80053358548 scopus 로고    scopus 로고
    • Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
    • Yin M, Silljé HH, Meissner M, van Gilst WH, de Boer RA. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 2011;10:85.
    • (2011) Cardiovasc Diabetol , vol.10 , pp. 85
    • Yin, M.1    Silljé, H.H.2    Meissner, M.3    Van Gilst, W.H.4    De Boer, R.A.5
  • 63
    • 84855492576 scopus 로고    scopus 로고
    • Granulocyte colony-stimulating factor treatment plus dipeptidylpeptidase- IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes
    • Zaruba MM, Zhu W, Soonpaa MH, Reuter S, Franz WM, Field LJ. Granulocyte colony-stimulating factor treatment plus dipeptidylpeptidase-IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes. Eur Heart J 2012;33:129-137.
    • (2012) Eur Heart J , vol.33 , pp. 129-137
    • Zaruba, M.M.1    Zhu, W.2    Soonpaa, M.H.3    Reuter, S.4    Franz, W.M.5    Field, L.J.6
  • 64
    • 58949102483 scopus 로고    scopus 로고
    • Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat
    • Poornima I, Brown SB, Bhashyam S, Parikh P, Bolukoglu H, Shannon RP. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 2008;1:153-160.
    • (2008) Circ Heart Fail , vol.1 , pp. 153-160
    • Poornima, I.1    Brown, S.B.2    Bhashyam, S.3    Parikh, P.4    Bolukoglu, H.5    Shannon, R.P.6
  • 65
    • 78149493266 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
    • Liu Q, Anderson C, Broyde A, Polizzi C, Fernandez R, Baron A et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010;9:76.
    • (2010) Cardiovasc Diabetol , vol.9 , pp. 76
    • Liu, Q.1    Anderson, C.2    Broyde, A.3    Polizzi, C.4    Fernandez, R.5    Baron, A.6
  • 66
    • 4344605042 scopus 로고    scopus 로고
    • Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy
    • DOI 10.1161/01.CIR.0000139339.85840.DD
    • Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004;110:955-961. (Pubitemid 39128621)
    • (2004) Circulation , vol.110 , Issue.8 , pp. 955-961
    • Nikolaidis, L.A.1    Elahi, D.2    Hentosz, T.3    Doverspike, A.4    Huerbin, R.5    Zourelias, L.6    Stolarski, C.7    Shen, Y.-T.8    Shannon, R.P.9
  • 67
    • 28144441354 scopus 로고    scopus 로고
    • Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy
    • DOI 10.1152/ajpheart.00347.2005
    • Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005;289: H2401-H2408. (Pubitemid 41698549)
    • (2005) American Journal of Physiology - Heart and Circulatory Physiology , vol.289 , Issue.6
    • Nikolaidis, L.A.1    Elahi, D.2    Shen, Y.-T.3    Shannon, R.P.4
  • 68
    • 79951979265 scopus 로고    scopus 로고
    • Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy
    • Vyas AK, Yang KC, Woo D, Tzekov A, Kovacs A, Jay PY et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 2011;6:e17178.
    • (2011) PLoS One , vol.6
    • Vyas, A.K.1    Yang, K.C.2    Woo, D.3    Tzekov, A.4    Kovacs, A.5    Jay, P.Y.6
  • 69
    • 84855317103 scopus 로고    scopus 로고
    • Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet
    • Mells JE, Fu PP, Sharma S, Olson D, Cheng L, Handy JA et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 2012;302:G225-G235.
    • (2012) Am J Physiol Gastrointest Liver Physiol , vol.302
    • Mells, J.E.1    Fu, P.P.2    Sharma, S.3    Olson, D.4    Cheng, L.5    Handy, J.A.6
  • 70
    • 0038202937 scopus 로고    scopus 로고
    • Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats
    • DOI 10.1097/00004872-200306000-00012
    • Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003;21: 1125-1135. (Pubitemid 36667866)
    • (2003) Journal of Hypertension , vol.21 , Issue.6 , pp. 1125-1135
    • Yu, M.1    Moreno, C.2    Hoagland, K.M.3    Dahly, A.4    Ditter, K.5    Mistry, M.6    Roman, R.J.7
  • 72
    • 1442311383 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion
    • DOI 10.1161/01.CIR.0000120505.91348.58
    • Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-965. (Pubitemid 38282847)
    • (2004) Circulation , vol.109 , Issue.8 , pp. 962-965
    • Nikolaidis, L.A.1    Mankad, S.2    Sokos, G.G.3    Miske, G.4    Shah, A.5    Elahi, D.6    Shannon, R.P.7
  • 74
    • 84860390563 scopus 로고    scopus 로고
    • A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans
    • Read PA, Hoole SP, White PA, Khan FZ, O'Sullivan M, West NE et al. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ Cardiovasc Interv 2011;4:266-272.
    • (2011) Circ Cardiovasc Interv , vol.4 , pp. 266-272
    • Read, P.A.1    Hoole, S.P.2    White, P.A.3    Khan, F.Z.4    O'Sullivan, M.5    West, N.E.6
  • 75
    • 84857111888 scopus 로고    scopus 로고
    • Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
    • Read PA, Khan FZ, Dutka DP. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart 2012;98:408-413.
    • (2012) Heart , vol.98 , pp. 408-413
    • Read, P.A.1    Khan, F.Z.2    Dutka, D.P.3
  • 77
    • 77951934948 scopus 로고    scopus 로고
    • DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease
    • Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ Cardiovasc Imaging 2010;3: 195-201.
    • (2010) Circ Cardiovasc Imaging , vol.3 , pp. 195-201
    • Read, P.A.1    Khan, F.Z.2    Heck, P.M.3    Hoole, S.P.4    Dutka, D.P.5
  • 78
    • 78650023641 scopus 로고    scopus 로고
    • Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)-rationale, design and first interim analysis
    • Theiss HD, Brenner C, Engelmann MG, Zaruba MM, Huber B, Henschel V et al. Safety and efficacy of SITAgliptin plus GRanulocyte-colony-stimulating factor in patients suffering from Acute Myocardial Infarction (SITAGRAMI-Trial)- rationale, design and first interim analysis. Int J Cardiol 2010;145:282-284.
    • (2010) Int J Cardiol , vol.145 , pp. 282-284
    • Theiss, H.D.1    Brenner, C.2    Engelmann, M.G.3    Zaruba, M.M.4    Huber, B.5    Henschel, V.6
  • 79
    • 33644682164 scopus 로고    scopus 로고
    • Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure
    • Thrainsdottir I, Malmberg K, Olsson A, Gutniak M, Rydén L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res 2004;1:40-43.
    • (2004) Diab Vasc Dis Res , vol.1 , pp. 40-43
    • Thrainsdottir, I.1    Malmberg, K.2    Olsson, A.3    Gutniak, M.4    Rydén, L.5
  • 80
    • 33845293219 scopus 로고    scopus 로고
    • Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
    • DOI 10.1016/j.cardfail.2006.08.211, PII S1071916406011092
    • Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-699. (Pubitemid 44881367)
    • (2006) Journal of Cardiac Failure , vol.12 , Issue.9 , pp. 694-699
    • Sokos, G.G.1    Nikolaidis, L.A.2    Mankad, S.3    Elahi, D.4    Shannon, R.P.5
  • 81
    • 77749273703 scopus 로고    scopus 로고
    • Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure
    • Halbirk M, Nørrelund H, Møller N, Holst JJ, Schmitz O, Nielsen R et al. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am J Physiol Heart Circ Physiol 2010;298: H1096-H1102.
    • (2010) Am J Physiol Heart Circ Physiol , vol.298
    • Halbirk, M.1    Nørrelund, H.2    Møller, N.3    Holst, J.J.4    Schmitz, O.5    Nielsen, R.6
  • 82
    • 79951702236 scopus 로고    scopus 로고
    • Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: A retrospective analysis of the LifeLink database
    • Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011;34:90-95.
    • (2011) Diabetes Care , vol.34 , pp. 90-95
    • Best, J.H.1    Hoogwerf, B.J.2    Herman, W.H.3    Pelletier, E.M.4    Smith, D.B.5    Wenten, M.6
  • 83
    • 80455158258 scopus 로고    scopus 로고
    • Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): Study protocol for a randomized controlled trial
    • Scholte M, Timmers L, Bernink FJ, Denham RN, Beek AM, Kamp O et al. Effect of additional treatment with EXenatide in patients with an Acute Myocardial Infarction (EXAMI): study protocol for a randomized controlled trial. Trials 2011;12:240.
    • (2011) Trials , vol.12 , pp. 240
    • Scholte, M.1    Timmers, L.2    Bernink, F.J.3    Denham, R.N.4    Beek, A.M.5    Kamp, O.6
  • 84
    • 79957634425 scopus 로고    scopus 로고
    • Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes
    • Ovalle F. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Clin Ther 2011;33:393-407.
    • (2011) Clin Ther , vol.33 , pp. 393-407
    • Ovalle, F.1
  • 85
    • 79955397107 scopus 로고    scopus 로고
    • Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies
    • Giorgino F, Leonardini A, Natalicchio A, Laviola L. Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. J Endocrinol Invest 2011;34:69-77.
    • (2011) J Endocrinol Invest , vol.34 , pp. 69-77
    • Giorgino, F.1    Leonardini, A.2    Natalicchio, A.3    Laviola, L.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.